Wilson Therapeutics has closed a €37.4M Series B financing to advance its late-stage development program for Wilson’s disease. The company will present its ongoing Phase II trial of WTX101-201, the company’s treatment for this disease, at the upcoming 50th International Liver Congress 2015.
Approximately 1 in 15000 people worldwide have Wilson Disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damage. Wilson Disease is universally fatal if left undiagnosed and untreated. The poster that the company will present, titled “WTX101-201: Phase II Study of Bis-choline Tetrathiomolybdate in Newly Diagnosed Wilson Disease Patients,” will be displayed in the Clinical Trials in Progress session on April 25.
Jonas Hansson, Chief Executive Officer of Wilson Therapeutics, said: “We are pleased with this significant support from our new as well as existing investors,